Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice | Synapse
March 3, 2026
Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice
Key Points
Resistance mechanisms can lead to treatment failure in HER2+ breast cancer, complicating effective management.
Key findings show that post-trastuzumab deruxtecan strategies may enhance therapeutic effectiveness by targeting specific pathways.
Focused analysis explores biomarker-driven approaches to refine treatment plans for HER2-positive and HER2-low patients.
Insights into clinical practice underscore the importance of understanding drug resistance in personalizing breast cancer therapies.